Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults

Limited real-world data on dolutegravir (DTG) plus lamivudine (3TC) for HIV-1-infected individuals have been reported. This study aimed to evaluated the real-world efficacy and safety of DTG + 3TC in ART-naïve HIV-1-infected adults in China. This real-world prospective observational cohort study enr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jin, Chen, Dabiao, Wen, Zhiwei, Du, Yanzhang, Huang, Zhanlian, Zhong, Huijun, Wang, Yanhao, Yin, Sichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4850
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592519/
https://www.ncbi.nlm.nih.gov/pubmed/36281149
http://dx.doi.org/10.1097/MD.0000000000031100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592519/
https://www.ncbi.nlm.nih.gov/pubmed/36281149
http://dx.doi.org/10.1097/MD.0000000000031100

Ejemplares similares